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Abstract
Background
Insulin therapy in type 2 diabetes may increase mortality and cancer incidence, but the
impact of different types of basal insulins on these endpoints is unclear. Compared to the
traditional NPH insulin, the newer, longer-acting insulin analogues detemir and glargine
have shown benefits in randomized controlled trials. Whether these advantages translate
into lower mortality among users in real life is unknown.
Objective
To estimate the differences in all-cause and cause-specific mortality rates between new
users of basal insulins in a population-based study in Finland.
Methods
23 751 individuals aged40 with type 2 diabetes, who initiated basal insulin therapy in
2006–2009 were identified from national registers, with comprehensive data for mortality,
causes of death, and background variables. Propensity score matching was performed on
characteristics. Follow-up time was up to 4 years (median 1.7 years).
Results
2078 deaths incurred. With NPH as reference, the adjusted HRs for all-cause mortality
were 0.39 (95% CI, 0.30–0.50) for detemir, and 0.55 (95% CI, 0.44–0.69) for glargine. As
compared to glargine, the HR was 0.71 (95% CI, 0.54–0.93) among detemir users. Com-
pared to NPH, the mortality risk for both cardiovascular causes as well as cancer were also
significantly lower for glargine, and especially for detemir in adjusted analysis. Furthermore,
the results were robust in various sensitivity analyses.
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Conclusion
In real clinical practice, mortality was substantially higher among users of NPH insulin as
compared to insulins detemir or glargine. Considering the large number of patients who
require insulin therapy, this difference in risk may have major clinical and public health impli-
cations. Due to limitations of the observational study design, further investigation using an
interventional study design is warranted.
Introduction
The goal of insulin use in type 2 diabetes is to prevent microvascular and macrovascular com-
plications associated with uncontrolled hyperglycemia. However, insulin therapy itself may
increase the risk of cardiovascular events, cancer, and mortality [1–2], but the impact of differ-
ent types of basal insulins on these endpoints is unclear.
In patients with type 2 diabetes basal insulin therapy is usually initiated with the conven-
tional NPH (neutral protamine Hagedorn) insulin, or a newer, longer-acting basal insulin ana-
logue detemir or glargine. NPH has been the predominant basal insulin in clinical use for
several decades, but the use of glargine and detemir has gradually risen subsiding the use of
NPH insulin. [3] However, the substantially higher cost of analogues (covered by patents) cre-
ates a financial burden on patients and insurers, and since in addition the superiority of newer
analogues has not been proven [4], NPH insulin is recommended as the initial choice for insu-
lin treatment for patients with type 2 diabetes in many countries.[5]
The three insulins differ in their molecular structure and pharmacokinetic action. Notably,
compared to the peak absorption of 4–5 hours after injection of NPH [6], detemir and glargine
have a relatively longer and peakless action [7–8]. Detemir and glargine have shown advan-
tages, such as a lower risk of hypoglycaemia and weight gain, over NPH in randomized clinical
trials (RCTs) [9–10], as well as in short observational studies [11]. However, it is not known
whether these potential advantages translate into additional benefits on morbidity and mortal-
ity in the long term. RCTs are often of short duration, whereby hard endpoints such as cardio-
vascular and cancer mortality cannot be recognized. Moreover, the patients randomized into
clinical trials are not necessarily representative of the general population, because patients with
advanced age, co-morbidities, or a history of hypoglycaemias may have been excluded. On the
other hand, in clinical practice the choice of insulin may be selective according to patient pro-
file, and the type of insulin may be switched over time, blurring possible associations in retro-
spective studies. Overall, the mortality risk associated with insulin use has not been extensively
examined in real-life, and well-designed studies for comparative safety between modern insulin
types are needed.
The aim of this nationwide, register-based longitudinal study was to investigate the differ-
ences in the safety of insulins NPH, detemir, and glargine in terms of all-cause and cause-spe-
cific mortality among real-life patients with type 2 diabetes.
Methods
Ethics statement
This is a register-based study with anonymous data and no patient contact. The study protocol
was approved by the Ethical Review Board of the Hjelt Institute, University of Helsinki Medical
Faculty. The research permission numbers to use the data were obtained from the Social
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Study population
The study population comprised 23 751 Finnish patients with type 2 diabetes, who at age 40
years and older had initiated therapy with basal insulin (NPH, detemir, or glargine) between
January 1, 2006, and December 31, 2009 (Fig 1). The participants were insulin-naïve, i.e. they
had no earlier prescriptions for basal insulins. During the study period, all three basal insulins
were available, and they were 100% reimbursed for type 2 diabetes patients in Finland. Further-
more, these were the only basal insulins on the market and there were no recommendations
regarding insulin preference for specific patient groups at that time.
Sources of data
The patients were linked to nation-wide administrative registers through the unique personal
identity code assigned to each citizen. In Finland, all individuals who have a prescription for
drug treatment of diabetes are entitled to full reimbursement of medical expenses. This requires
a detailed certificate from the treating physician. Expert physicians of the Social Insurance Insti-
tution of Finland (KELA) validate the certificates for diagnosis, and KELA maintains a register
of the patients. All purchased and reimbursed medications are recorded in the Finnish Prescrip-
tion Register (FPR) and Finnish Registry for Reimbursed Medication (FRM), with generic
name, prescribed amount in defined daily doses (DDD) as defined byWHO, and date of pur-
chase. The Finnish Hospital Care Register (FHCR), administered by the National Institute for
Health andWelfare (THL), contains information on hospitalization events such as diagnosis
(ICD codes), and dates of admission and discharge. Mortality data was retrieved from Statistics
Finland (SF), where the vital status is collected for all Finnish citizens into the Finnish Causes of
Death Register (FCDR)—irrespective whether they die in Finland or abroad. [12] Consequently,
the mortality coverage of the follow-up was virtually complete. [13] These same registers have
been utilized in several recent diabetes, [14–15] and mortality related studies [16].
Using these registers we were able to identify practically every patient with type 2 diabetes,
who during the study period was entitled to reimbursement of insulin (Category 103 with
ICD-10 International Classification of Diseases—the 10th revision [ICD-10] diagnosis code
Fig 1. Study population flow chart.
doi:10.1371/journal.pone.0151910.g001
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E11) in Finland. The three basal insulins were compared for all-cause and cause-specific mor-
tality. FHCR was used to gather data on hospitalizations due to severe hypoglycaemia (ICD-10
diagnosis code E10.00 and E11.00). Prior and current use of insulin and sulfonylurea was
obtained from the FPR, based on purchase information since 1995. Information on hospitaliza-
tions due to other reasons, or information on the use of other medication were not obtained.
Statistical methods
The index date was defined as the date of the first purchase of a prescribed basal insulin. Drug
exposure periods started at the date of purchase, and the length of the exposure period was esti-
mated according to the number of DDD’s and the average daily dosage, as contained in the
purchases over the entire follow-up. To avoid introducing gaps between consecutive drug
exposure periods, a 15% grace period was added to the length of the underlying purchase. The
time dependent exposure variable, “current use of NPH, detemir, or glargine”, was based on
these exposure periods. In case of a switch between the basal insulins we assumed that the
patient had the most recent insulin in use.
Any follow-up time that was not covered by the exposure periods of the three insulins
was assigned to a category”Unknown”. The deaths which occurred during this time were not
accounted for in any basal insulin group but were analysed separately as a group of
“Unknown deaths”.
Propensity score matching
To reduce potential selection bias, and to balance the three insulin groups, PS matching tech-
nique [17] was used to form a subcohort (N = 9 363) with 3 121 patients in each basal insulin
group. Propensity scores [18]—the probabilities to initiate insulin NPH, detemir and glargine—
were calculated for each participant conditional on the following covariates: Age at baseline
(10-year age groups), gender, prior use of non-basal insulin (yes/no), prior use of sulpholnylur-
eas (yes/no), prior hospitalization due to severe hypoglycaemia (yes/no), and years from diagno-
sis of diabetes at the index date. These variables could potentially influence the selection of
insulin type by the attending physician. For each patient, PS were calculated separately within
each calendar year of cohort entry (2006–2009). The treatment groups were then balanced
across these covariates in a 1:1:1 ratio by selecting the group with the smallest number of initia-
tors, and then matching persons (according to the closest PS) were picked from the two compar-
ator groups. We used Euclidean distance in the 3-dimensional space spanned by the three PS to
identify the closest matches.
Kaplan-Meier curves for survival were estimated for the cohorts prior to and after matching,
and Cox's proportional hazards (PH) models were used to calculate adjusted hazard ratios
(HRs) with 95% confidence intervals [CI]) for mortality associated with insulin use. For all-
cause mortality analysis P values of less than 0.05 were considered statistically significant. For
cause-specific analyses Bonferroni correction was applied. As matching only assures balance in
PS variables between treatment groups at baseline, the Cox’s PH model was adjusted for all PS-
variables as well as for the time dependent variables “current use of non-basal insulin”, “current
use of sulfonylurea”, and “switch of basal insulin”. The PH assumption for basal insulin, age
and gender was examined by plotting the stratified Kaplan-Meier curves. R software was used
for the analyses.
Sensitivity analyses
To address potential bias due to unknown exposure to basal insulin we performed two sensitivity
analyses. In the first, follow-up periods of unknown exposure were censored, and in the second,
Basal Insulins and Mortality
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we assumed that patients continued the use of the most recent basal insulin during the periods of
unknown exposure. In the main sensitivity analysis we did not exclude persons who had previous
exposure to non-basal insulin, because these consisted mostly of brief use of a short acting insulin
during periods of ill health or pregnancy. To address this potential bias we performed a sensitiv-
ity analysis where patients with previous use of non-basal insulin were excluded. In the outcome
analysis, switching between basal insulins was adjusted for by including a time dependent indica-
tor variable of the first switch in insulin regimen. Furthermore sensitivity analyses where follow-
up was censored at the time of the first switch was performed, and also where follow-up time
periods of overlapping use of basal insulin were censored. (See S1 Table)
Results
Study patients
Between January 1, 2006 and December 31, 2009, there were 23 751 patients with type 2 diabe-
tes, who initiated use of NPH (N = 8535, 35.9%), detemir (N = 4749, 20.0%), or glargine
(N = 10 467, 44.1%), at age 40 or over (Fig 1). Mean age in the total cohort was 65.5 years. 58%
were male. Prior to matching, the baseline distributions of gender and age were similar between
insulin groups, although there were slightly less initiators of detemir in the older age groups
(70–79 and>79 years) (Table 1).
For other variables there were no major differences except for the calendar year of start of
the first insulin: The number of prescriptions for NPH declined during the follow up, whereas
there was a rising trend for prescriptions for detemir and glargine with time. To reduce the
potential bias, these covariates have been taken into account in the propensity score model.
After PS matching, these and also other differences between the insulin groups were evened
out (Table 1).
All-cause mortality
Survival curves of the total cohort and the PS matched cohort are in Fig 2. Among the 23 751
patients there were 2078 deaths: 681 among new users of NPH, 149 of detemir and 556 of glar-
gine. In the PS matched cohort of 9 363 patients, there were 620 deaths during the up to 4-year
follow-up time (median 1.7, interquartile range 0.8 to 2.2 years). These deaths were divided as
follows: During exposure to NPH: 183 deaths (absolute rate 55/1000 patient years, 95% CI 48
to 63), detemir: 90 deaths (absolute rate 22, 95% CI 18 to 27), and glargine: 146 deaths (abso-
lute rate 31, 95% CI 26 to 37). Considering NPH as reference, the adjusted hazard ratio (HR)
for detemir was 0.39 (95% CI, 0.30 to 0.50) and for glargine 0.55 (95% CI, 0.44 to 0.69). When
compared to glargine, the adjusted HR for detemir was 0.71 (95% CI, 0.54 to 0.93) (Table 2).
Cause-specific mortality
In the PS matched cohort, cardiovascular diseases were the most frequent cause of death
(N = 275, 44.4%), followed by cancer (N = 183, 29.5%), gastrointestinal diseases (N = 42,
6.8%), respiratory diseases (N = 29, 4.7%), and deaths of other causes (N = 91, 14.7%)
(Table 3).
Considering NPH as reference, the adjusted HR for detemir for cardiovascular mortality
was 0.42 (95% CI, 0.28 to 0.61), and for glargine 0.65 (95% CI, 0.47 to 0.91). With exposure to
glargine as reference the HR for detemir was 0.64 (95% CI, 0.43 to 0.95).
For cancer mortality the adjusted HR for detemir was 0.23 (95% CI, 0.14 to 0.40), and for
glargine 0.35 (95% CI, 0.22 to 0.54) with NPH as reference. When compared to glargine, the
HR for detemir was 0.67 (95% CI, 0.38 to 1.18).
Basal Insulins and Mortality
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For the deaths due to gastrointestinal diseases and with NPH as reference, the adjusted HR
for both detemir and glargine tended to be reduced (0.45, 95% CI, 0.19 to 1.06; 0.44, 95% CI,
0.19 to 1.00, respectively).
Sensitivity analyses
Among the PS matched population there were 3979 patients who had periods during which
the type of insulin could not be verified in registers, equalling to 9% of the total follow-up time.
During these periods of unknown exposure 201 deaths were recorded. The lack of information
Table 1. Baseline characteristics for the three basal insulin initializers prior to matching and for the propensity score matched cohort.
Baseline* variable Unmatched cohort, N = 23751 Propensity score matched cohort, N = 9363
Insulin
NPH,
N = 8535
Detemir,
N = 4749
Glargine,
N = 10467
Insulin
NPH,
N = 3121
Detemir,
N = 3121
Glargine,
N = 3121
no. % no. % no. % P-
value1
no. % no. % no. % P-
value1
Gender
Male 4977 58.3 2773 58.4 6158 58.8 0.8 1808 57.9 1823 58.4 1823 58.4 0.9
Female 3558 41.7 1976 41.6 4309 41.2 1313 42.1 1298 41.6 1298 41.6
Age, years
40–49 771 9.0 506 10.7 975 9.3 <0.001 299 9.6 288 9.2 287 9.2 1.0
50–59 1965 23.0 1231 25.9 2448 23.4 703 22.5 735 23.6 722 23.1
60–69 2423 28.4 1479 31.1 2918 27.9 903 28.9 890 28.5 899 28.8
70–79 2077 24.3 1000 21.1 2474 23.6 716 22.9 727 23.3 724 23.2
80+ 1299 15.2 533 11.2 1652 15.8 500 16.0 481 15.4 489 15.7
Prior use of sulpholnylurea
No 2919 34.2 1653 34.8 3290 31.4 <0.001 1190 38.1 1196 38.3 1195 38.3 1.0
Yes 5616 65.8 3096 65.2 7177 68.6 1931 61.9 1925 61.7 1926 61.7
Prior use of non- basal insulin
No 8154 95.5 4396 92.6 9898 94.6 <0.001 2941 94.2 2955 94.7 2950 94.5 0.7
Yes 381 4.5 353 7.4 569 5.4 180 5.8 166 5.3 171 5.5
Prior hospitalizations due to severe
hypoglycaemia
No 7808 91.5 4428 93.2 9587 91.6 <0.001 2882 92.3 2908 93.2 2912 93.3 0.3
Yes 727 8.5 321 6.8 880 8.4 239 7.7 213 6.8 209 6.7
Time since type 2 diabetes diagnosis
1 2376 27.8 1077 22.7 2394 22.9 <0.001 924 29.6 933 29.9 925 29.6 0.8
>1-2 506 5.9 324 6.8 630 6.0 190 6.1 175 5.61 170 5.45
>2-5 1917 22.5 1069 22.5 2239 21.4 642 20.6 659 21.12 686 21.98
>5-10 2745 32.2 1671 35.2 3645 34.8 966 31.0 930 29.8 936 29.99
>10- 991 11.6 608 12.8 1559 14.9 399 12.8 424 13.59 404 12.94
Calendar year at start of follow-up
2006 3657 42.9 55 1.2 451 4.3 <0.001 55 1.8 55 1.8 55 1.8 1.0
2007 2544 29.8 732 15.4 2595 24.8 732 23.5 732 23.5 732 23.5
2008 1433 16.8 1684 35.5 3718 35.5 1433 45.9 1433 45.9 1433 45.9
2009 901 10.6 2278 48.0 3703 35.4 901 28.9 901 28.9 901 28.9
* Baseline is the date of purchase of ﬁrst basal insulin.
1P-value based on Pearson’s Chi-Square test
doi:10.1371/journal.pone.0151910.t001
Basal Insulins and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0151910 March 31, 2016 6 / 13
Fig 2. Kaplan-Meier survival curves for the initializers of the three basal insulins, Panel (A):
unmatched cohort (n = 23 751), Panel (B): propensity score matched cohort (n = 9363), Log-rank p-
values<0.001 for detemir vs. NPH, and glargine vs. NPH in both panels. Log-rank p-value for detemir vs.
glargine <0.001 in Panel (A) and 0.005 in Panel (B).
doi:10.1371/journal.pone.0151910.g002
Basal Insulins and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0151910 March 31, 2016 7 / 13
was typically due to hospitalization, or treatment in a nursing home, where insulin was sup-
plied by the institution, and thus no prescription data was available from registers. Also, 5.5%
of the cohort had previously used insulin for a short period, typically during an acute disease
requiring treatment with a short-acting insulin. During follow-up 1130 patients switched their
initial basal insulin treatment (825 from NPH, 219 from detemir, and 88 from glargine). We
performed sensitivity analyses to account for these and other unmeasured confounders, and to
estimate potential biases. (S1 Table) In these analyses the differences in HRs for mortality
between the insulin types remained essentially unaltered. We found no evidence for interaction
with gaps or switches of insulin use, or with cumulative exposure (measured in time). More-
over, the results were comparable for the total unmatched cohort. (S1 Table)
Discussion
We found considerable differences in mortality risks related to the three basal insulins in a
large, nationwide follow-up study of real-life patients in routine practice. The adjusted risk for
Table 2. All-causemortality estimated by Cox’s proportional hazardsmodel using propensity score matched data. Reference category in brackets.
Variables (Reference category) Categories Hazard
ratio
95% CI P-value
Basal insulin (NPH) Detemir 0.39 0.30, 0.50 <0.001
Glargine 0.55 0.44, 0.69 <0.001
Unknown* 3.12 2.52, 3.85 <0.001
Gender (Male) Female 0.73 0.62, 0.86 <0.001
Age-group, (40–49 years) 50–59 1.17 0.72, 1.90 0.52
60–69 2.16 1.38, 3.38 <0.001
70–79 4.15 2.66, 6.47 <0.001
80+ 8.03 5.12, 12.59 <0.001
Prior use of non-basal** insulin at start of follow-up (No) Yes 1.24 0.94, 1.62 0.12
Time dependent current use of non-basal** insulin during follow-up (No) Yes 0.66 0.53, 0.82 <0.001
Prior use of sulpholnylurea at start of follow-up (No) Yes 1.38 1.00, 1.91 0.05
Time dependent current use of sulpholnylurea during follow-up (No) Yes 0.88 0.70, 1.11 0.29
Prior hospitalization due to severe hypoglycaemia at start of follow-up (No) Yes 0.67 0.38, 1.20 0.18
Time dependent number of prior hospitalizations due to severe hypoglycaemia at start of follow-up
(None)
1–2 1.75 1.03, 2.98 0.04
3 2.51 1.16, 5.46 0.02
Time dependent switch of insulin during follow-up: purchase of other study insulin than the initiated
study insulin (No)
Yes 1.73 1.32, 2.28 <0.001
Time from diagnosis (years) deﬁned as time from ﬁrst purchase of diabetes medication or time of
reimbursement decision whichever occur ﬁrst (1 year)
>1-2 1.00 0.66, 1.53 0.99
>2-5 1.26 0.94, 1.69 0.13
>5-10 0.83 0.60, 1.14 0.25
>10 1.12 0.80, 1.59 0.51
Calendar year of purchase of ﬁrst basal insulin, (2006) 2007 1.10 0.64, 1.88 0.74
2008 1.15 0.66, 1.98 0.62
2009 1.62 0.90, 2.90 0.11
* Category “Unknown” comprises the time periods where type of insulin was not available in database.
** “Prior use of non-basal insulin” denotes a prescription for a non-basal insulin.
There were 692 and 201 deaths in the unmatched, and matched cohorts respectively, during a period when the insulin type used could not be veriﬁed
from registers. These deaths were taken into account using sensitivity analyses. (See S1 Table, Models 2 and 3.)
doi:10.1371/journal.pone.0151910.t002
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all-cause mortality was 61% lower among users of detemir, and 45% lower for glargine, com-
pared to the treatment with the conventional NPH insulin. Furthermore, detemir was associ-
ated with a significant risk reduction of 29% in comparison to glargine. Both cardiovascular
and cancer related mortality were significantly higher in the NPH group.
A recent systematic review revealed a substantial lack of studies using hard endpoints such
as cardiovascular mortality among users of different insulin regimen. [19] Also, we did not find
any studies comparing cancer-related mortality between different insulins. Newer, longer act-
ing basal insulins detemir and glargine have shown benefits over NPH in RCTs, but it has not
been clearly demonstrated whether these advantages translate into lower mortality. Even long-
term RCTs have a selected population, and they may not be representative of the general
patient population and routine practice. Modern electronic patient records offer a source for
studies comparing treatments in real-life settings, but these are difficult to conduct because of
the many potential variables and changes in treatment over time.
Strengths and limitations
In this regard, our study with patients from clinical practice has several strengths. We used
national registers with reliable prescription and mortality data with a follow-up of 13 397 per-
son-years in a propensity score -matched population. At the start of follow-up all participants
were basal insulin-naïve. Additionally, our large database allowed adjustment for possible con-
founding factors, including switches and gaps in treatment. As demonstrated by the sensitivity
analyses, the magnitudes of the adjusted HRs for mortality were robust and consistent both for
the parent cohort of 23 751 participants as well as for the PS matched subcohort. Our observa-
tional study does not prove causality, but the adjusted and robust findings suggest more than
just association.
A crucial question is whether the insulin groups were comparable at baseline. To reduce this
potential bias we have used multiple statistical approaches. For example, the large database
enabled the use of seven relevant covariates attributable to the choice of insulin by the pre-
scriber. However, many important clinical variables were unavailable, and are thus not
included in the PS model. For instance, we did not obtain information on lifestyle factors, body
mass index, or comorbidities. Also clinical parameters such glucose, HbA1c levels, or renal
function during the study are lacking. All these could potentially affect the choice of basal insu-
lin by the prescribing physician. On the other hand, it is plausible that high risk patients would
more likely be prescribed with longer acting insulin, which would drive our results towards
null. For instance, the lower risk for hypoglycaemia shown in RTCs could have favoured the
initiation of glargine or detemir for persons with cardiovascular disease, for whom
Table 3. Cause-specific mortality of users of detemir and glargine with insulin NPH as reference in the propensity score matched cohort.
Cause-speciﬁc mortality (ICD-10 diagnosis code) Insulin NPH Detemir Glargine
N = 3121 N = 3121 N = 3121
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Cardiovascular diseases (I00-I99) 1.0 0.42 0.28, 0.61 P<0.001 0.65 0.47, 0.91 P = 0.012
Cancer and neoplasms (C00-D48) 1.0 0.23 0.14, 0.40 P<0.001 0.35 0.22, 0.54 P<0.001
Digestive system (K00-K93) 1.0 0.45 0.19, 1.06 P = 0.064 0.44 0.19, 1.00 P = 0.049
Respiratory system (J00-J99) 1.0 0.18 0.04, 0.89 P = 0.036 0.76 0.28, 2.05 P = 0.59
Other causes of death 1.0 0.70 0.38, 1.30 P = 0.26 0.68 0.68, 1.27 P = 0.23
To account for multiple testing p-values smaller than 0.05/5 = 0.001 are considered statistically signiﬁcant (Bonferroni correction).
doi:10.1371/journal.pone.0151910.t003
Basal Insulins and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0151910 March 31, 2016 9 / 13
hypoglycaemia could be anticipated to be more harmful. This could conversely benefit the
NPH group in our study. Furthermore, the history of previous hospitalizations due to severe
hypoglycaemia was taken into account in the adjusted analyses. Nevertheless, the possibility
remains that physicians would have preferred the earlier generation insulin NPH to the newer
analogues for some type of patients, leading to bias. However, this scenario would not clearly
explain the significant differences we found between glargine and detemir. Also, the lack of
data on concomitant oral medication for diabetes before or during the study period may con-
stitute a bias. However, according to the national, evidence-based guidelines, generally only
metformin is to be continued when add-on insulin treatment is initiated for patients with type
2 diabetes. Also, these guidelines did not give a preference for the type of insulin at initiation.
Thus, we do not expect that differences, in for instance metformin use, would have guided the
choice of insulin at baseline. We also lacked the information of insulin dosage and the partici-
pants’ body mass index during the study and were not able to examine dose–response relation-
ships to support causal effects. However, these two parameters are apt to change, and they
would be extremely difficult to control for in a study with real-life patients.
Second, detemir was the last to enter clinical use, and in our study there were only 55 dete-
mir users in 2006, the number gradually increasing thereafter. This was taken into account by
use of propensity scores. Furthermore, there was no difference in the availability or costs for
the patient between the insulins during the study period. The gradual replacement of NPH
with longer acting detemir and glargine in our study over the years 2006–2009 reflects the real-
life situation in Finland and elsewhere.[3–4]
Third, the follow-up time was relatively short but in a real-life setting with changing treat-
ment patterns it is difficult to sustain long periods of the same treatment. In our study popula-
tion 14% of the patients switched the insulin first prescribed during the follow-up. By
comparison, in a study of patients with type 2 diabetes treated in primary care in the UK
approximately every fourth patient had changed the initial glargine and every third patient the
initial NPH or detemir to some other preparation during a follow up of 24 months. [20]
Finally, there were 201 deaths in the PS matched population which occurred at a time when
insulin use could not be verified by registers. This gap was typically associated with treatment
in an institution, often at the end of life. The sensitivity analyses indicate that taking these
deaths into account did not significantly change the results.
Comparison with previous studies and possible explanations
Hypoglycaemia is the most common side effect of insulin therapy. [21] Several studies have
reported an association between severe hypoglycaemia and mortality, especially in high risk
patients. [22–23] Furthermore, large follow-up studies examining the benefits of stringent glu-
cose control in type 2 diabetes–often pursued by using insulin therapy- have shown that while
microvascular complications are reduced [24], the side effects of intensified treatment—espe-
cially hypoglycaemia and weight gain—may increase mortality. [25] However, most of the
aforementioned studies have not specified the type of insulin therapy prescribed, which, in the
light of our findings, merits further analysis. For comparison, in a study during 2001 to 2008,
adding insulin as compared to adding sulpholnylurea to patients on metformin monotherapy
was associated with 44% higher risk of all-cause mortality; a comparable difference to our find-
ing between basal insulins. [26]
A difference in hypoglycaemia risk is a potential explanation for our results, especially as
cardiovascular disease was the most frequent (44%) cause of death in our study. Compared to
NPH, both longer-acting insulins, detemir and glargine, have been shown to provoke less
hypoglycaemia.[9] In a previous study using Finnish national registers (N = 75 000), new users
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of detemir and glargine who were followed up for 4 years, had a 31% and 16% lower risk of a
severe hypoglycaemic episode respectively.[14] We found a 58% lower risk of cardiovascular
mortality for detemir, and a 35% lower risk for glargine. Of note, prior hospitalization due to
severe hypoglycaemia was adjusted for in the PS matching.
Another possible explanation for our findings is a difference in weight gain among the
patients with different basal insulins. Commencing insulin therapy often leads to an increase in
body weight, which may be associated with cardiovascular disease, cancer and increased mor-
tality. [27] Glargine, and especially detemir have been shown to cause less weight gain. [11,28]
However, we lacked the information about weight changes during follow-up and were subse-
quently unable to account for this.
Cancer related mortality
In our study, 30% of the deaths were due to cancer. The choice of insulin appeared to have an
even greater impact on cancer related mortality than on cardiovascular mortality. In the
adjusted analyses with NPH as comparator, detemir and glargine were associated with a 77%
and 65% lower risk, respectively. Since the development of cancer takes many years, it seems
extraordinary that we found a significant difference between the treatment groups in cancer
related mortality during our follow-up of up to 4 years. However, a similar effect has been
observed previously [29] suggesting that pre-existing malignant cells may rapidly proliferate
into fulminant cancer when stimulated by the growth hormone action of insulin. Another
hypothesis suggests that hyperglycaemia may play a role, whereby cancer growth could be
delayed among those with well-controlled diabetes and preclinical cancer. [30] Thirdly, it has
not been studied whether insulin therapy could negatively affect anti-cancer treatment thereby
increasing mortality. We also analysed cancer mortality by censoring the first 12 months of
insulin use (S1 Table, Model 10). This risk was 48% and 44% lower among detemir and glar-
gine users, respectively, compared to NPH, but the number of events was small, and the finding
was not statistically significant.
Although insulin studies with cancer mortality as an endpoint are few, insulin therapy has
been associated with an increased cancer incidence. [31] In a German Insurance study of 127
000 patients, dose-adjusted use of glargine was associated with an increased risk for cancer
compared with users of human insulin. [29] On the other hand, the randomized, controlled
ORIGIN trial found no significant difference in cancer incidence between glargine and stan-
dard care during a follow-up of over 6 years. [32] Also, a record linkage study of over 70 000
patients in France comparing cancer incidence among new users of glargine, detemir, and
human basal insulin did not find differences in risk. However, this study censored the first 6 to
12 months of exposure. [33] For detemir a possible association with cancer has not been exten-
sively studied, but meta-analyses did not show any increase in cancer incidence during short
RCTs. [34–35] In all, the large differences in cancer mortality in our study warrant randomised
trials and may call for distinguishing the insulin type in older studies.
In conclusion, risk of all-cause, cardiovascular, and cancer mortality associated with insulin
therapy in patients with type 2 diabetes, was significantly lower with detemir and glargine in
comparison with NPH use. Overall, the choice of insulin may have more impact on the risks
and benefits of intensive glucose treatment than has hitherto been considered.
Supporting Information
S1 Table. Sensitivity analysis for risk of all-cause mortality for the users of insulins detemir
and glargine with NPH as reference.
(DOCX)
Basal Insulins and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0151910 March 31, 2016 11 / 13
Acknowledgments
Presented in part in the form of a poster at the American Diabetes Association 74th Scientific
sessions, 13–17Jun, 2014, San Francisco, CA.
We thank Mr. Andy Langdon, Helsinki, Finland, for proof reading, and Hannu Kautiainen,
PhD, for comments on the manuscript.
Author Contributions
Conceived and designed the experiments: AYS FJH SC JH PK. Performed the experiments:
AYS FJH TES SC JH PK. Analyzed the data: AYS FJH TES SC JH PK. Contributed reagents/
materials/analysis tools: AYS FJH SC JH PK. Wrote the paper: AYS FJH TES SC JH PK.
Administrative, technical, and material support: AYS FJH TES SC JH PK.
References
1. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related
outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab.
2013; 98: 668–77. doi: 10.1210/jc.2012-3042 PMID: 23372169
2. Gamble J-M, Simpson SH, Eurich DT, Majumdar SR, Johnson A. Insulin use and increased risk of mor-
tality in type 2 diabetes: a cohort study. Diabetes, Obesity and Metabolism, 2010; 12: 47–53. doi: 10.
1111/j.1463-1326.2009.01125.x PMID: 19788429
3. Jing L, Avorn J, Kesselheim AS. Trends in Medicaid reimbursements for insulin from 1991 through
2014. JAMA Int Med 2015; 175.10: 1681–6.
4. Tylee T, Hirsch IB. Costs AssociatedWith Using Different Insulin Preparations. JAMA 2015; 314.7:
665–6 doi: 10.1001/jama.2015.7032 PMID: 26284715
5. National institute for Health and Clinical Excellence (NICE). Type 2 diabetes, newer agents. Available
at: www.nice.org.uk. (Accessed 27Mar2015)
6. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and
pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insu-
lin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;
49:2142–8. PMID: 11118018
7. Goldman-Levine JD, Lee KW. Insulin detemir–a new basal insulin analog. Ann Pharmacother 2005;
39:502–7. PMID: 15657117
8. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the
long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and pla-
cebo. Diabetes Care 2000; 23:644–9. PMID: 10834424
9. Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, et al. Safety, effective-
ness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1
diabetes: systematic review and network meta-analysis. BMJ 2014; 349:g5459. doi: 10.1136/bmj.
g5459 PMID: 25274009
10. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in
type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008; 81:184–9. doi: 10.1016/j.diabres.
2008.04.007 PMID: 18495286
11. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ. Insulin detemir improves glycae-
mic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insu-
lin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup
of the PREDICTIVE study. Diabetes Obes Metab 2007; 9:418–27. PMID: 17391170
12. Gissler M, Haukka J. Finnish health and social welfare registers in epidemiological research. Norsk Epi-
demiologi 2004; 14: 113–120.
13. Lahti R, Penttilä A. The validity of death certificates: routine validation of death certification and its
effects on mortality statistics. Forensic Sci Int 2001; 115: 15–32. PMID: 11056267
14. Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P. Evaluation of the incidence and
risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a
Finnish register linkage study. Pharmacoepidem Drug Saf 2013; 22:1326–35.
15. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E. Pioglitazone and bladder cancer
risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015; 58, 493–504. doi: 10.
1007/s00125-014-3456-9 PMID: 25481707
Basal Insulins and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0151910 March 31, 2016 12 / 13
16. Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, et al. Estradiol-based post-
menopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015;
22: 976–83 doi: 10.1097/GME.0000000000000450 PMID: 25803671
17. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal
effects. Biometrika 1983; 70:41–55.
18. Rassen JA, Shelar AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity
score matching in cohort studies. Pharmacoepidem Dr S 2012; 21(S2): 69–80.
19. Price HI, AgnewMD, Gamble JM. Comparative cardiovascular morbidity and mortality in patients taking
different insulin regimens for type 2 diabetes: a systematic review. BMJ open 2015; 5:e006341. doi: 10.
1136/bmjopen-2014-006341 PMID: 25762229
20. Gordon J, Pockett RD, Tetlow AP, McEwan P, Home PD. A comparison of intermediate and long-acting
insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract
2010; 64:1609–1618. doi: 10.1111/j.1742-1241.2010.02520.x PMID: 20946269
21. UK Hypoglycemia Study Group. Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment
modalities and their duration. Diabetologia 2007; 50:1140–7. PMID: 17415551
22. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, et al. Severe hypoglycemia
and risks of vascular events and death. N Engl J Med 2010; 363:1410–8. doi: 10.1056/
NEJMoa1003795 PMID: 20925543
23. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK, et al. Hypoglycemia and Risk of Car-
diovascular Disease and All-Cause Mortality in Insulin-Treated PeopleWith Type 1 and Type 2 Diabe-
tes: A Cohort Study. Diabetes Care 2015; 38:316–322. doi: 10.2337/dc14-0920 PMID: 25492401
24. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control
in type 2 diabetes. N Engl J Med 2008; 359:1577–89. doi: 10.1056/NEJMoa0806470 PMID: 18784090
25. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control
and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabe-
tes trials: A position statement of the American Diabetes Association and a scientific statement of the
American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol
2009; 53:298–304. doi: 10.1016/j.jacc.2008.10.008 PMID: 19147051
26. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, et al. Association between intensifica-
tion of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mor-
tality among patients with diabetes. JAMA 2014; 311(22):2288–2296. doi: 10.1001/jama.2014.4312
PMID: 24915260
27. Adams KF, Leitzmann MF, Ballard-Barbash R, Albanes D, Harris TB, Hollenbeck A, et al. Body mass
and weight change in adults in relation to mortality risk. Am J Epidemiol 2014; 179:135–44. doi: 10.
1093/aje/kwt254 PMID: 24173550
28. Rossetti P, Porcellati F, Fanelli CG., Perriello G, Torlone E, Bolli GB. Superiority of insulin analogues
versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem 2008; 114:3–10. doi:
10.1080/13813450801900777 PMID: 18465353
29. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies
in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia
2009; 52:1734–44.
30. Yang X-L, Chan JCN. Diabetes, insulin and cancer risk. World J Diabetes 2012; 3:60–64 doi: 10.4239/
wjd.v3.i4.60 PMID: 22532884
31. Colmers IN, Bowker SL Tjosvold LA, Johnson JA. Insulin use and cancer risk in patients with type 2 dia-
betes: a systematic review and meta-analysis of observational studies. Diabetes Metab 2012; 38:485–
506. doi: 10.1016/j.diabet.2012.08.011 PMID: 23159131
32. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al. Basal insulin
and cardiovascular and other outcomes in dysglycemia. New Engl J Med. 2012; 367:319–28. doi: 10.
1056/NEJMoa1203858 PMID: 22686416
33. Fagot JP, Blotière PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk
of cancer compared with other basal insulins?: A French nationwide cohort study based on national
administrative databases. Diabetes Care 2013; 36:294–301. doi: 10.2337/dc12-0506 PMID: 22966091
34. Dejgaard A, Lynggaard H, Råstam J, ThomsenMK. No evidence of increased risk of malignancies in
patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009; 52,2507–12.
doi: 10.1007/s00125-009-1568-4 PMID: 19838665
35. KarlstadØ, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, et al. Use of insulin
and insulin analogs and risk of cancer—systematic review and meta-analysis of observational studies.
Curr Drug Saf 2014; 8:333–48.
Basal Insulins and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0151910 March 31, 2016 13 / 13
